Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090765 | 0.67 | CYP1A2 (0.52) | TGFBR1CYP1A2ACVR1BHTR2BSLC6A3 | |
| SCHEMBL22270337 | 0.66 | TGFBR1 (0.79) | TGFBR1ACVR1BCYP3A4ACVRL1ACVR1 | |
| SCHEMBL2598379 | 0.64 | TGFBR1 (1.00) | TGFBR1CYP3A4 | |
| SCHEMBL2596827 | 0.64 | TGFBR1 (1.00) | TGFBR1CYP3A4 | |
| SCHEMBL2596845 | 0.63 | TGFBR1 (0.48) | TGFBR1CYP1A2ACVR1BHTR2BSLC6A3 | |
| SCHEMBL22270336 | 0.63 | TGFBR1 (0.50) | TGFBR1CYP1A2ACVR1BHTR2BSLC6A3 | |
| SCHEMBL14253025 | 0.62 | CYP1A2 (0.44) | TGFBR1CYP1A2ACVR1BHTR2BSLC6A3 | |
| SCHEMBL16879386 | 0.62 | TGFBR1 (0.82) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL22270338 | 0.62 | TGFBR1 (0.79) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL29722227 | 0.61 | TGFBR1 (0.49) | TGFBR1CYP1A2ACVR1BHTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114540278-B | Microvascular in-vitro culture method and culture solution | 青岛大学 | 2023-11-21 | — | — | CN | claimed |
| CN-114540278-A | Microvessel in-vitro culture method and culture solution | 青岛大学 | 2022-05-27 | — | — | CN | claimed |
| EP-4665755-A1 | POLYPEPTIDES BINDING TO THE NEONATAL FC RECEPTOR | Ablynx N.V. (BE) | 2025-12-24 | — | — | EP | disclosed |
| EP-3365371-B1 | GITR AGONISTS | ABLYNX NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4562036-A1 | POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR | Ablynx NV (BE) | 2025-06-04 | — | — | EP | disclosed |
| CN-120077065-A | Polypeptides that bind to specific epitopes of neonatal Fc receptor | 阿布林克斯有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12291515-B2 | Pyrrolidine derivative and use thereof | WANG, Zheming (CN) | 2025-05-06 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4243933-A2 | THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING | The Jackson Laboratory (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116332818-A | Tetrahydropyrrole derivatives and their use | 王喆明 | 2023-06-27 | — | — | CN | disclosed |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | WANG, ZHEMING (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20220411733-A1 | Method and System for Converting Electricity into Alternative Energy Resources | UNIV CHICAGO (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411521-A1 | POLYPEPTIDES THAT BIND GLUCOCORTICOID-INDUCED TNFR FAMILY-RELATED RECEPTOR (GITR) | ABLYNX N.V. (BE) | 2022-12-29 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022104071-A9 | THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING | THE JACKSON LABORATORY (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114540278-A | Microvessel in-vitro culture method and culture solution | 青岛大学 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022104071-A2 | THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING | THE JACKSON LABORATORY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | TGFBR1 3602/4885CYP1A2 4290/4885ACVR1B 3335/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | TGFBR1 3602/4885CYP1A2 4290/4885ACVR1B 3335/4885 |
| US-20230192651-A1 | Pyrrolidine Derivative and Use Thereof | NAMPT, NAPRT, NNMT | TGFBR1 4284/4885CYP1A2 4199/4885ACVR1B 606/4885 |
| US-12291515-B2 | Pyrrolidine derivative and use thereof | NAMPT, NAPRT, NNMT | TGFBR1 4284/4885CYP1A2 4199/4885ACVR1B 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.